LETERMOVIR PRIMARY PROPHYLAXIS IS A PROTECTIVE FACTOR FOR SURVIVAL IN HEMATOPOIETIC CELL TRANSPLANT RECIPIENTS. DATA FROM THE FIRST PROSPECTIVE MULTICENTER STUDY IN LATIN AMERICA (EBMT 2026) - Mar 14, 2026 - Abstract #B097; Pres time: Mar 24, 2026; 06:00 PM - 07:00 PM; Location: VELAZQUEZ; "CMV seronegative donors, alternative donors, post-transplant Cyclophosphamide administration and T-cell depletion were compared in PET vs. LET groups: 12.43% vs. 30.73% (p<0.001), 56.94% vs. 87.32% (p<0.001), 51.73% vs. 80.98% (p<0.001), and 12.14% vs. 15.61% (p=0.24), respectively. Our cohort largely comprised patients at high risk of developing cs-CMVi and CMV-d. Notwithstanding that, LET primary prophylaxis effectively prevented CMV-related complications, reduced rehospitalizations and was a protective factor for survival. These data support the use of this antiviral for primary prophylaxis in seropositive aHCT patients in Latin American countries."
Clinical • Acute Lymphocytic Leukemia • Acute Myelogenous Leukemia • Bone Marrow Transplantation • Cytomegalovirus Infection • Graft versus Host Disease • Hematological Malignancies • Immunology • Infectious Disease • Leukemia • Transplantation
|
|
Fabian Herrera1; Diego Torres1; Lucas Tula2; Noelia Mañez3; Florencia Otermin4; Ana Laborde5; María Laura Pereyra6; Manuel Alderete7; Hugo Peretti8; María José Eusebio9; Silvina García Rojas9; Nicolás Lasserre1; Julieta Dalmaroni2; Facundo Arguello3; María Elena Silva4; María Luz González Ibañez5; Rocío Gago6; Santiago Adriani8; Rosana Jordán9
|